Danish pharma industry veteran Peter Drøidal highlights how he steered the Danish Novartis affiliate through the COVID-19 pandemic period, the strategy in place to navigate an increasingly challenging market access landscape, and the lessons that can be leveraged from the value-based agreement that Novartis was able to strike with the Danish authorities for one of its gene therapy products.
Denmark has a unique health data infrastructure with national registers and electronic medical journals for each patient. This data footprint is a true asset for Denmark in its bid to establish itself as a leading life science nation, but we still do not leverage it well enough
